Transfer from research/academia to clinical/regulated

Area of Science:

• Biopharmaceutical development
• Drug discovery and development
• Translational medicine

Background:

• Academic research plays a crucial role in early-stage drug discovery.
• Traditional methods for assessing biological drugs in academia have evolved.
• The need for robust early-stage assessment is critical for efficient drug development pipelines.

Purpose of the Study:

• To describe the adaptations in academia for assessing biological drug candidates.
• To highlight the collaborative efforts between academia, industry, and regulatory bodies.
• To discuss the challenges and advancements in bioanalytical techniques for biologicals.

Main Methods:

• Review of current academic approaches to assessing biological drug properties (PDs).
• Analysis of collaborative networks involving academia, industry, and regulatory agencies.
• Examination of advancements in bioanalytical techniques and regulatory guidance.

Main Results:

• Academia has adapted its methods for early-stage assessment of biological agents.
• Consortia involving industry, academia, and regulatory bodies are harmonizing bioanalytical techniques.
• Despite regulatory lag, collaborative groups are improving the identification of promising drug candidates.

Conclusions:

• Collaborative efforts are essential for advancing biological drug development from academia to industry.
• Enhanced early-stage assessment and harmonized techniques accelerate the progression of novel therapies.
• The relationship between academia and industry is increasingly collaborative, fostering innovation in drug development.